STOCK TITAN

Sutro Biopharma, Inc. - $STRO STOCK NEWS

Welcome to our dedicated page for Sutro Biopharma news (Ticker: $STRO), a resource for investors and traders seeking the latest updates and insights on Sutro Biopharma stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sutro Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sutro Biopharma's position in the market.

Rhea-AI Summary
Sutro Biopharma, Inc. (STRO) reported positive financial results for Q3 2023, with $321.1 million in cash and investments. The company presented encouraging data for luvelta in endometrial cancer and announced Dr. Hans-Peter Gerber as the new CSO. The upcoming ASH 2023 will feature updated data on luvelta's anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.49%
Tags
-
Rhea-AI Summary
Sutro Biopharma announces encouraging preliminary results from a Phase 1 study of luvelta in endometrial cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Sutro Biopharma to present at the 14th Annual World ADC Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
none
Rhea-AI Summary
Sutro Biopharma appoints Hans-Peter Gerber as Chief Scientific Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
management
-
Rhea-AI Summary
Sutro Biopharma CEO to participate in two investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
conferences
-
Rhea-AI Summary
Sutro Biopharma, Inc. (STRO) reported financial results for Q2 2023, highlighting enrollment for the REFRaME-O1 Phase 2/3 study of luveltamab tazevibulin for platinum-resistant ovarian cancer, a royalty agreement with Blackstone Life Sciences, and a cash runway into H1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.6%
Tags
conferences
Rhea-AI Summary
Sutro Biopharma reports Q1 2023 financial results and previews upcoming milestones
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
Sutro Biopharma, Inc.

Nasdaq:STRO

STRO Rankings

STRO Stock Data

345.86M
48.62M
0.95%
86.15%
3.86%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
SOUTH SAN FRANCISCO

About STRO

at sutro biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. our focus is aimed primarily on next generation cancer therapeutics — antibody conjugates and bispecific antibodies. unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. our approach to discovery, without the cell, is also transcending the the limitations of biologics manufacturing. sutro has the world’s only cgmp cell-free manufacturing facility located in san carlos, california. this state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. in addition to developing our own oncology pipeline, sutro biopharma is coll